Gland Pharma Ltd (GLAND)
₹2,972.00
Mkt cap
₹48,375 Cr
P/E ratio
42.20
P/B
4.72
Div yield
0.68%
ROE
10.70%
ROCE
15.10%
EPS (TTM)
₹70.43
Book value
₹629
52W range
1,597–2,972
Sector
Healthcare
Price history
Previous close
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
NSE GLANDBSE 543245
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
0.00% from high₹2,972
₹1,597+86.12% from low₹2,972
Current
₹2,972.00
Prev close
₹2,939.70
Day
+1.10%
Price performance
1D
+1.10%
1W
+2.99%
1M
+14.26%
3M
+29.87%
6M
+73.96%
1Y
+58.84%
YTD
+73.21%
Financials
Revenue, profit & margin
P/E ratio
42.2×
GLAND is 24% above the sector median of 34.0×
GLAND42.2×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,209 | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 | |
| Expenses | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | 1,311 | |
| Operating Profit | 294 | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 | |
| OPM % | 24% | 24% | 23% | 23% | 19% | 21% | 26% | 24% | 24% | 21% | 26% | 29% | 27% | |
| Other Income | 38 | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 | |
| Interest | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 | |
| Depreciation | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 | |
| Profit before tax | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 | |
| Tax % | 26% | 33% | 32% | 35% | 34% | 36% | 32% | 35% | 31% | 35% | 28% | 28% | 27% | |
| Net Profit | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 | |
| EPS in Rs | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.21 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +2.28% · closed higher next day 10 of last 19
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 6 Nov '23◦ | 14 Feb '24◦ | 22 May '24◦ | 6 Aug '24◦ | 4 Nov '24◦ | 3 Feb '25◦ | 20 May '25◦ | 5 Aug '25◦ | 3 Nov '25◦ | 28 Jan '26◦ | 15 May '26◦ | 10 Aug '26◦ |
| Earnings day | +4.97% | −2.72% | +4.95% | −3.75% | +13.78% | −3.66% | +4.87% | −0.37% | −3.05% | +6.53% | +15.43% | +9.64% |
| +1 day | +3.20% | +2.62% | +5.18% | −3.77% | +15.24% | −1.10% | +3.22% | −0.35% | −3.72% | +9.29% | +20.49% | +8.39% |
| +5 days | +2.66% | −2.64% | +3.19% | −7.06% | +9.54% | −4.11% | +1.83% | −0.74% | −6.80% | +9.44% | +24.92% | +7.17% |
| +15 days | +12.69% | −9.48% | +3.50% | −12.24% | +6.67% | +5.55% | +12.25% | −4.74% | −8.94% | +8.92% | +22.49% | +7.79% |
| +30 days | +14.84% | −8.27% | +2.60% | −14.09% | +10.35% | +5.13% | +24.59% | +2.96% | −16.19% | −3.73% | +31.95% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 20 Per Sh | 20.00 | 11 Aug '26 | 11 Aug '26 |
Shareholding
as of Jun 202651.77%Promoter
Promoters51.77%0.06
FIIs8.74%1.45
DIIs30.44%2.92
Public9.06%1.54
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| GLAND | ₹2,932.40 | 42.22 | 48,375 | 0.68% | 317 | +47.09% | 1,800 | +19.57% | 15.11% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports6
Concall transcripts57
RECAug 2024TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024
Credit ratings4
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Sep - Gland Pharma schedules one-on-one investor meeting with Kotak Mutual Fund on September 9, 2026.Conclusion Of USFDA Inspection At Company''s Facilities Situated At Visakhapatnam 1 Sep - USFDA routine GMP inspection at Visakhapatnam facility concluded on September 1, 2026 with zero Form 483 observations.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 31 AugShareholder Meeting / Postal Ballot-Scrutinizer''s Report 26 AugShareholder Meeting / Postal Ballot-Outcome of AGM 25 Aug - Gland Pharma held its 48th AGM; FY26 revenue rose 14% to ₹64,307 million, PAT up 47%.